British Journal of Clinical Pharmacology
DOI:10.1111/bcp.12508
High- and low-dose allergen challenges in asthmatic patients using inhaled corticosteroids
Correspondence
Wha-Yong Lee, Thomas Southworth, Steven Booth & Dave Singh
Keywords
Dr Wha-Yong Lee MBChB MRCP, The University of Manchester, Manchester Academic Health Science Centre, Medicines Evaluation Unit, University Hospital South Manchester NHS Foundation Trust, NIHR South Manchester Respiratory and Allergy Clinical Research Facility, Manchester M23 9LT, UK. Tel.: +44 161 946 4050 Fax: +44 161 946 1459 E-mail: [email protected] -----------------------------------------------------------------------
Manchester Academic Health Science Centre; University Hospital South Manchester NHS Foundation Trust; NIHR South Manchester Respiratory and Allergy Clinical Research Facility, Medicines Evaluation Unit, The University of Manchester, Manchester, UK
allergen challenge, asthma, inhaled corticosteroids, induced sputum -----------------------------------------------------------------------
Received 27 March 2014
Accepted 5 September 2014
Accepted Article Published Online
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
11 September 2014
• Eosinophilic airway inflammation is a feature of allergic asthma. • Inhaled allergen challenge studies in inhaled corticosteroid-naïve asthmatics have been used to assess the effects of novel anti-inflammatory drugs on eosinophilic airway inflammation.
AIMS
WHAT THIS STUDY ADDS
METHODS
• High-dose allergen challenge causes eosinophilic airway inflammation in patients taking inhaled corticosteroids, and may be a suitable model for investigating novel anti-inflammatory drugs in this population.
Twenty-eight asthmatic patients taking ICS (beclomethasone equivalent
DOI:10.1111/bcp.12508
High- and low-dose allergen challenges in asthmatic patients using inhaled corticosteroids
Correspondence
Wha-Yong Lee, Thomas Southworth, Steven Booth & Dave Singh
Keywords
Dr Wha-Yong Lee MBChB MRCP, The University of Manchester, Manchester Academic Health Science Centre, Medicines Evaluation Unit, University Hospital South Manchester NHS Foundation Trust, NIHR South Manchester Respiratory and Allergy Clinical Research Facility, Manchester M23 9LT, UK. Tel.: +44 161 946 4050 Fax: +44 161 946 1459 E-mail: [email protected] -----------------------------------------------------------------------
Manchester Academic Health Science Centre; University Hospital South Manchester NHS Foundation Trust; NIHR South Manchester Respiratory and Allergy Clinical Research Facility, Medicines Evaluation Unit, The University of Manchester, Manchester, UK
allergen challenge, asthma, inhaled corticosteroids, induced sputum -----------------------------------------------------------------------
Received 27 March 2014
Accepted 5 September 2014
Accepted Article Published Online
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
11 September 2014
• Eosinophilic airway inflammation is a feature of allergic asthma. • Inhaled allergen challenge studies in inhaled corticosteroid-naïve asthmatics have been used to assess the effects of novel anti-inflammatory drugs on eosinophilic airway inflammation.
AIMS
WHAT THIS STUDY ADDS
METHODS
• High-dose allergen challenge causes eosinophilic airway inflammation in patients taking inhaled corticosteroids, and may be a suitable model for investigating novel anti-inflammatory drugs in this population.
Twenty-eight asthmatic patients taking ICS (beclomethasone equivalent
